In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Betting on Beads

Executive Summary

Four year old Luminex appears to be in the right place at the right time, but it faces increasing competition in a confusing field. The company has, in only a few short years, launched two generations of products, completed a successful IPO, and captured the attention of life scientists, who are scrambling for inexpensive, fast tools that can do genetic and proteomic analysis. Luminex has a simple-to-use multiplexing platform, which is flexible and inexpensive enough to be easily adapted to fields as diverse as genomics and clinical diagnostics.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts